Oral anabolic androgenic steroid

Oxandrolone (Anavar)

Oxandrolone is an anabolic steroid; its label gives single-dose half-lives of 10.4 h (younger) and 13.3 h (elderly).1 In 2023 FDA found its tablets were withdrawn from sale for safety or effectiveness reasons.2

Strong evidenceGet the app

Level after one dose

Oxandrolone (Anavar) after one dose: 50% at ~10 h, 25% at 20 h, 12.5% at 30 h.

Drawn from the half-life in the app's model, ~10 h. The model's figures

1

How Milligram users log it

Track your protocol with Milligram.

5%The 11th most tracked compound in Milligram: of people who track compounds in Milligram logged Oxandrolone (Anavar) in the last 90 days.

Schedule

  1. Daily79%
  2. Every other day10%
  3. Twice a week7%
  4. Weekly3%
  5. Less often1%
Among people with three or more logged doses, by the average gap between their doses.

Logged doses

Half of people logged between 20 and 40 mg per dose; the median was 25 mg.

Each person's usual logged amount. The bar starts at zero; the shaded part is the middle half, the mark the median.

Tracked alongside

The share of people logging Oxandrolone (Anavar) who also logged each.

From dose logs in the Milligram app, 90 days to 15 November 2026. Aggregated and anonymous. This describes what people recorded, not what anyone should take.

Oxandrolone is an anabolic steroid, chemically 17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one, and the Oxandrin label on DailyMed, issued January 2006, describes tablets of 2.5 mg or 10 mg.1 The figures row above is the app's own, and the label's figures appear in the pharmacokinetics and dose tables below. The label's indications include adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma.1 The label also states that anabolic steroids have not been shown to enhance athletic ability.1

FDA's Federal Register notice of 13 September 2023 states that the tablets were initially approved on July 21, 1964 (2.5 mg) and November 5, 2001 (10 mg) under an application held by Gemini Laboratories.2 The Strong Evidence label shown with this compound is the app's own grade and not a conclusion of the sources: the notice records that an FDA advisory committee in January 1984 "unanimously concluded that there was no evidence of efficacy for oxandrolone",2 and the trials below include gains, results with no benefit and a longer time on the ventilator in one trial.

The label describes anabolic steroids as synthetic derivatives of testosterone and states that complete dissociation of anabolic and androgenic effects has not been achieved.1 The label states that anabolic steroids suppress the gonadotropic functions of the pituitary and that, during exogenous administration of anabolic androgens, endogenous testosterone release is inhibited through inhibition of pituitary luteinizing hormone.1 In 262 HIV-infected men given oxandrolone at 20, 40 or 80 mg daily, treatment was "associated with significant suppression of sex hormone-binding globulin, luteinizing hormone, follicle-stimulating hormone, and total and free testosterone levels".6

4

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~10 h
Bioavailability
97%
Typical dose
5–50 mg/day
Route
Oral
Time to peak
~1.5 h

The app's figures for oxandrolone are a half-life of 10 hours, a bioavailability of 97% and a time to peak of 1.5 hours. The US label's own figures differ or are absent, as the table shows.1

Table 4.1Half-life and pharmacokinetics3 rows
MeasureApp figureSource figure
Half-life~10 hMean elimination half-life of 10.4 hours in younger volunteers and 13.3 hours in elderly subjects, each after a single dose of Oxandrin.1
Bioavailability97%The label text gives no bioavailability figure; a study of a buccal oxandrolone preparation in medium-chain triglyceride oil, designed to evaluate relative bioavailability in adults, reported a mean bioavailability of 62.5%, with variable exposures in adults and neonates.1,7
Time to peak~1.5 hThe label gives no time to peak value and states that no significant differences between younger and elderly volunteers were found for time to peak, peak plasma concentration or AUC after a single dose.1

The chart below is an illustrative model built from the app's half-life of 10 hours and time to peak of 1.5 hours, not a measured curve; the label gives no time to peak and single-dose half-lives of 10.4 and 13.3 hours.1 Its one dosing interval is the 10 mg every 12 hours of a cited trial.8

Level over 3 days

Interval between doses

Level, as a share of the peak after one 10 mg dose

As studied: every 12 hours8. As logged in Milligram: the share of people with three or more logged doses on each schedule (How Milligram users log it).

An illustration from a pharmacokinetic model using a half-life of 10 hours. It is not a measured level or a suggested dose.

5

Human studies

Table 5.1Human studies7 rows
Study and yearDesignPeopleDose and lengthMain result
Wolf and colleagues, 20068Randomised, double-blind, multicentre; stopped at a planned interim analysis.81 adults with burns of 20% to 60% of total body surface area.10 mg every 12 hours or placebo; treatment length not stated in the source text.Hospital stay 31.6 ± 3.1 days with oxandrolone and 43.3 ± 5.3 days with placebo (P under 0.05).
Porro and colleagues, 201211Randomised, placebo-controlled, single-centre; patients also randomised to exercise or standard care.222 children aged 0 to 18 with burns over 30% of total body surface area.0.1 mg/kg twice daily for 12 months (70 children) or placebo (152); assessments up to 4 years after therapy.Lower resting energy expenditure; with exercise, more lean body mass and muscle strength; better height percentile and bone mineral content than controls, with the largest effect at ages 7 to 18; no deleterious side effects attributed to long-term administration, in the authors' conclusion; the record gives no effect sizes.
Gault and colleagues, 2011 and 202110,12Randomised, double-blind, placebo-controlled, 36 UK hospital departments.106 girls with Turner syndrome aged 7 to 13 years at recruitment, receiving growth hormone; 14 withdrew.0.05 mg/kg/day, maximum 2.5 mg/day, or placebo from 9 years of age.Final height 4.6 cm higher than placebo (95% CI 1.9 to 7.2; n = 82) in 2011; 4.1 cm higher (95% CI 1.6 to 6.6; n = 92) in the 2021 final analysis.
Grunfeld and colleagues, 20066Randomised, double-blind, placebo-controlled; 12 weeks, then open-label oxandrolone for 12 weeks.262 HIV-infected men with 10% to 20% documented weight loss or a low body mass index.Placebo or 20, 40 or 80 mg daily.Weight rose 1.1 ± 2.7 kg on placebo and 1.8, 2.8 and 2.3 kg at 20, 40 and 80 mg; only the 40 mg weight gain was greater than placebo.
Bauman and colleagues, 20133Randomised, placebo-controlled, blinded, 16 Veterans Affairs spinal cord injury services.212 inpatients with spinal cord injury and stage III or IV pressure ulcers.20 mg/day (108) or placebo (104) until healed or 24 weeks.Target ulcers healed in 24.1% on oxandrolone and 29.8% on placebo (difference -5.7 percentage points, 95% CI -17.5 to 6.8; P = 0.40).
Schroeder and colleagues, 20044Randomised, double-blind, placebo-controlled.32 healthy men aged 60 to 87 (20 on oxandrolone, 12 on placebo).20 mg/day for 12 weeks, with a check 12 weeks after stopping.At 12 weeks lean body mass rose 3.0 ± 1.5 kg and total body water 2.9 ± 3.7 kg, and strength rose on four lifts and total fat fell 1.9 ± 1.0 kg, all more than on placebo; 12 weeks after stopping, lean mass and strength were no longer different from baseline and the fat decrease was sustained.
Bulger and colleagues, 20049Randomised, double-blind, placebo-controlled; primary end point time on the ventilator.41 ventilator-dependent surgical and trauma patients (18 oxandrolone, 23 placebo).10 mg by mouth twice daily; length of treatment not stated in the source text.Time on the ventilator 21.7 days with oxandrolone against 16.4 days with placebo (P = 0.03); no difference in infectious complications, acute respiratory distress syndrome or multiple organ failure scores; longer intensive care stay, no difference in total hospital stay.

In 29 sedentary women with a mean age of 74.9 years doing resistance training three times a week for 12 weeks, oxandrolone 10 mg a day increased whole-body lean tissue by 2.6 kg (95% CI 1.0 to 4.2) beyond placebo with training, without augmenting muscle function or functional performance beyond that of resistance training alone.13 In a secondary analysis of a randomised trial in 93 boys with Klinefelter syndrome aged 4 to 12, those given 0.06 mg/kg a day for 2 years had a lower percent body fat score at 2 years after adjustment for age and baseline (0.29 ± 0.76 against 0.81 ± 0.72, P = 0.009) and lower triglycerides, and also lower HDL cholesterol and faster advancement of bone age.14 Lou and colleagues, World Journal of Emergency Surgery, 2025, pooled 14 randomised burn trials (2,822 patients) of androgen analogs, including oxandrolone and nandrolone decanoate, and reported fewer surgical procedures (standardised mean difference -1.25; p = 0.04), a lower length of stay per percent of body surface burned (-1.07; p = 0.007), more weight gain (0.58) and lean mass (1.30; both p < 0.001), no improvement in donor-site healing (p = 0.116), no mortality difference (relative risk 1.04, 95% CI 0.47 to 2.32) and unchanged infection rates (relative risk 0.83, 95% CI 0.67 to 1.02).15 The pooled trials had non-commercial funding, and the review's own funding came from hospital and provincial research foundations in China, with no competing interests declared.15

Funding listed in the PubMed records, all from National Institutes of Health institutes: Bulger, NIDDK;9 Schroeder, NIA and NCRR;4 Porro, NICHD, NIGMS and others;11 Davis, NINDS, NIDDK and NICHD.14,18 The Mavros record lists author affiliations at Takeda and Novartis and no conflict statement.13

Deeper analysis: oxandrolone in severe burns (Wolf and colleagues, 2006)

Wolf and colleagues, Journal of Burn Care and Research, 2006, enrolled 81 adults with burns of 20% to 60% of total body surface area in a multicentre trial of oxandrolone 10 mg every 12 hours against placebo on length of hospital stay.8 The study was stopped halfway through projected enrollment because of a significant difference between groups found on planned interim analysis.8 Length of stay was 31.6 ± 3.1 days with oxandrolone and 43.3 ± 5.3 days with placebo (P under 0.05).8 The authors' conclusion pairs oxandrolone use with monitoring of hepatic transaminases.8 The PubMed record for this trial gives no adverse event counts, deaths by group, funder, author disclosure or limitations beyond the early stop, while the 2025 meta-analysis cites ALT above 100 U/L in 19.1% for this trial.15

Deeper analysis: Turner syndrome trials (Gault and colleagues, 2011; Menke and colleagues, 2010)

Gault and colleagues, BMJ, 2011, ran a randomised, double-blind, placebo-controlled trial in 36 UK paediatric endocrinology departments of girls with Turner syndrome receiving growth hormone.10 Of 106 participants recruited, 14 withdrew and 82 of 92 had reached final height at the time of analysis, and final height was 4.6 cm greater (95% CI 1.9 to 7.2) with oxandrolone than with placebo.10 The effects of oxandrolone and late pubertal induction "were not additive, so using both had no advantage".10 The 2021 final analysis of all 92 girls, in Archives of Disease in Childhood, gave 4.1 cm (95% CI 1.6 to 6.6) for oxandrolone, while the effect of late pubertal induction was no longer significant (2.7 cm, 95% CI -0.8 to 6.1, n = 56, against 3.8 cm in 2011).12 Between 1999 and 2009, 197 adverse events were reported, 10 of them serious and involving hospital admission for procedures; four could have been related to oxandrolone or ethinylestradiol: acne, persistent hypertension (oxandrolone or placebo was stopped and later restarted), abnormal liver function (the participant elected to stop growth-promoting treatment) and episodic hot flushes in a girl later revealed to have received placebo, and no virilisation was reported.10 The authors state that the 82 girls at final height fell short of the target sample size of 100 and that two breaks in production of oxandrolone 2.5 mg tablets led to protocol deviations, so that "the results may underestimate the true effect of oxandrolone".10 Funding came from the Scottish Executive Chief Scientist Office, then the British Society for Paediatric Endocrinology and Diabetes, with a contribution to pharmacy staff costs from the Child Growth Foundation, and the disclosures name no oxandrolone maker.10 Menke and colleagues, Journal of Clinical Endocrinology and Metabolism, 2010, randomised 133 girls on growth hormone to placebo or oxandrolone at 0.03 or 0.06 mg/kg/day from age 8.16 Adult height gain, defined as adult height minus predicted adult height, was 9.5 ± 4.7 cm at the lower dose against 7.2 ± 4.0 cm on placebo (P = 0.02); at the higher dose it was 8.3 ± 4.7 cm, not significantly different from placebo (P = 0.3), partly because of accelerated bone maturation.16 Breast development was slower on both doses (P = 0.02 and 0.05) and more girls reported virilization on 0.06 mg/kg than on placebo (P < 0.001), and the authors discouraged the conventional dose because of its low benefit to risk ratio.16 The PubMed record lists the publication type Research Support, Non-U.S. Gov't but names no funder and no author disclosure.

Deeper analysis: HIV-associated weight loss in men (Grunfeld and colleagues, 2006)

Grunfeld and colleagues, Journal of Acquired Immune Deficiency Syndromes, 2006, randomised 262 HIV-infected men with weight loss to placebo or oxandrolone 20, 40 or 80 mg daily in a double-blind trial.6 Body weight rose in all groups, including placebo, and body cell mass rose from baseline in all groups.6 At 12 weeks only the weight gain at 40 mg and the body cell mass gains at 40 and 80 mg were greater than those on placebo.6 The record's adverse findings are the hormone suppression and significant increases in transaminases and LDL with decreases in HDL.6 The first author is at the University of California San Francisco and the Department of Veterans Affairs Medical Center, and the PubMed record lists the publication type Research Support, Non-U.S. Gov't but names no funder, no disclosure and no limitations statement.6

Deeper analysis: pressure ulcers in spinal cord injury (Bauman and colleagues, 2013)

Bauman and colleagues, Annals of Internal Medicine, 2013, ran a placebo-controlled, blinded trial in 16 Veterans Affairs spinal cord injury services, and 212 of 779 screened inpatients with stage III or IV pressure ulcers were randomised.3 Healed target ulcers were 24.1% on oxandrolone and 29.8% on placebo (difference -5.7 percentage points, 95% CI -17.5 to 6.8; P = 0.40), and 16.7% against 15.4% retained a healed ulcer at 8 weeks of follow-up (difference 1.3 percentage points; P = 0.70).3 The authors state that oxandrolone "showed no benefit over placebo for improving healing".3 No serious adverse events were related to oxandrolone, while liver enzyme levels were elevated in 32.4% of oxandrolone recipients and 2.9% of placebo recipients.3 The authors list as limitations that selection of severe wounds may have reduced treatment response and that approximately one third of patients did not complete the study in the treatment and placebo groups, and the study was terminated after a futility analysis.3 The funder was the US Department of Veterans Affairs.3

6

Doses reported in studies and on the label

The app's typical dose range is 5 to 50 mg a day.

Table 6.1Doses reported in studies and on the label4 rows
SourceDoseFrequencyLength
US label, adults12.5 mg to 20 mg daily2 to 4 divided dosesCourse of 2 to 4 weeks, usually adequate per the label
US label, children1Total daily dose up to 0.1 mg per kilogram of body weightNot statedMay be repeated intermittently, per the label
US label, geriatric patients15 mgTwice dailyNot stated
Grunfeld and colleagues, 2006, HIV weight loss620, 40 or 80 mgDaily12 weeks, then open-label 20 mg for 12 weeks

The label carries a boxed warning, written for androgenic anabolic steroid therapy as a class, that reports peliosis hepatis, "a condition in which liver and sometimes splenic tissue is replaced with blood-filled cysts"; these cysts have been associated with liver failure and are often not recognized until life-threatening liver failure or intra-abdominal hemorrhage develops.1 The same warning reports liver cell tumors, most often benign but with fatal malignant tumors reported, and blood lipid changes, including decreased high-density lipoproteins and sometimes increased low-density lipoproteins, that "may be very marked" and are associated with increased risk of atherosclerosis.1 The label's warnings add that cholestatic hepatitis and jaundice may occur with 17-alpha-alkylated androgens at a relatively low dose, and its adverse reactions list rarely hepatic necrosis and death with cholestatic jaundice.1 It states that some virilizing changes in women are irreversible even after prompt discontinuance of therapy, and that in children androgen therapy may accelerate bone maturation without compensatory gain in linear growth, which results in compromised adult height.1

In 15 healthy subjects given oxandrolone 5 or 10 mg twice daily with warfarin, the mean S-warfarin half-life rose from 26 to 48 hours, microscopic hematuria occurred in 9 of 15 and gingival bleeding in 1 of 15.1

In the HIV weight loss trial, treatment was "generally well tolerated but accompanied by significant increases in transaminases and low-density lipoprotein as well as decreases in high-density lipoprotein".6 In the pressure ulcer trial no serious adverse events were related to oxandrolone, and liver enzyme levels were elevated in 32.4% on oxandrolone and 2.9% on placebo (P under 0.001).3 In the burn meta-analysis, the authors' summary reports transaminase elevations in adults of 19% against 5% (p = 0.002), worded as placebo in the summary and as children in the Discussion, and a non-significant overall risk ratio of 1.82 (95% CI 0.52 to 6.42; p = 0.34) for treatment-related hepatic dysfunction or edema.15 In 14 healthy young men given 10 mg twice daily for 14 days, plasminogen rose from 100% to 174% by day 7, PAI-1 fell at day 3 (16 to 7 mg/dL) and clotting factors II and V rose by day 14, while factors VII, VIII and X and the 22% fall in fibrinogen did not change significantly; the authors describe a state of potential hypercoagulability that appears to be counterbalanced by increased fibrinolytic activity.17 In a trial of 80 prepubertal boys with Klinefelter syndrome given 0.05 mg/kg for 2 years, boys on oxandrolone had 20.5 times higher odds of reaching gonadarche (95% CI 6.5 to 77.8) and 28.1 times higher odds of reaching pubarche (95% CI 8.8 to 110.4), with gonadarche at 9.8 ± 1.5 years against 12.1 ± 1.0 years on placebo.18

8

Bloodwork and markers

Sources in this part

  1. 1Savient Pharmaceuticals, 2006

The app lists liver enzymes, lipids and hematocrit as markers for oxandrolone. The label's laboratory-test section lists periodic liver function tests because of the hepatotoxicity associated with 17-alpha-alkylated androgens, periodic serum lipid levels, and periodic hemoglobin and hematocrit checks for polycythemia in patients receiving high doses of anabolic steroids.1

The label states that oxandrolone is classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and has been assigned to Schedule III (non-narcotic).1 On December 16, 2022 FDA notified Gemini and other holders of approved applications for oxandrolone tablets that it believes a potential problem associated with oxandrolone tablets is sufficiently serious to warrant removal of the drug products from the market.19 FDA announced in the Federal Register of June 28, 2023 that it was withdrawing approval of NDA 013718, effective June 28, 2023.19

FDA wrote that "the benefit-risk profile of the drug product is unfavorable without substantial evidence to support effectiveness".2 It also wrote that "New clinical studies would first need to be conducted to address the concerns described above".2 A correction published on 7 October 2026 extended the determination to the generic applications of Par Pharmaceutical, Roxane Laboratories, Sandoz and Upsher Smith that reference Oxandrin.19 WADA's 2026 Prohibited List places oxandrolone in S1.1, anabolic androgenic steroids when administered exogenously, in the class S1 anabolic agents.5 The class is prohibited at all times, in and out of competition, and all its substances are non-Specified Substances.5

The label text gives no bioavailability figure and no time to peak value, and the buccal bioavailability of 62.5% belongs to a different preparation and route.1,7 The burn meta-analysis authors describe "extreme heterogeneity" (I2 of 95.0% or more) among the trials it pooled and call for cautious interpretation.15

What is the half-life of Anavar?

The half-life of oxandrolone is 10.4 hours in younger volunteers and 13.3 hours in elderly subjects on the US label, each after a single dose, and the app uses 10 hours.1

Is Anavar approved by FDA?

FDA announced that it withdrew approval of the Oxandrin application effective June 28, 2023, and determined that the tablets were withdrawn from sale for reasons of safety or effectiveness.19,2

Is Anavar banned by WADA?

WADA's 2026 Prohibited List names oxandrolone among anabolic androgenic steroids in S1.1, prohibited at all times, in and out of competition.5

Is Anavar a controlled substance?

The US label states that oxandrolone has been assigned to Schedule III (non-narcotic) under the Anabolic Steroids Control Act of 1990.1

Does Anavar lower testosterone?

In 262 HIV-infected men with weight loss, oxandrolone at 20, 40 or 80 mg daily was associated with significant suppression of total and free testosterone, luteinizing hormone, follicle-stimulating hormone and sex hormone-binding globulin.6 In 80 prepubertal boys with Klinefelter syndrome given 0.05 mg/kg for 2 years, serum concentrations of testicular hormones and gonadotropins were not different between groups, although gonadarche came earlier on oxandrolone.18

Does Anavar affect cholesterol?

The label's class warning for androgenic anabolic steroids states that blood lipid changes include decreased high-density lipoproteins and sometimes increased low-density lipoproteins, and that the changes may be very marked.1

Does Anavar affect the liver?

The label's class warning for androgenic anabolic steroids names peliosis hepatis and liver cell tumors, including reports of fatal malignant tumors, and its warnings state that cholestatic hepatitis and jaundice may occur with 17-alpha-alkylated androgens at a relatively low dose.1 In 212 spinal cord injury inpatients on 20 mg a day, liver enzyme levels were elevated in 32.4% on oxandrolone and 2.9% on placebo.3

What did trials find for Anavar in burns?

In a multicentre trial of 81 adults with burns of 20% to 60% of total body surface area, stopped at a planned interim analysis, hospital stay was 31.6 ± 3.1 days with oxandrolone and 43.3 ± 5.3 days with placebo.8 A 2025 meta-analysis of 14 burn trials reported no mortality difference (relative risk 1.04, 95% CI 0.47 to 2.32) and higher transaminase elevations in adults (19% against 5%, p = 0.002).15

13

References

  1. Savient Pharmaceuticals. Oxandrin (oxandrolone tablets, USP) CIII, prescribing information, issued January 2006. DailyMed. DailyMed label
  2. US Food and Drug Administration. Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register 88 FR 62799, 13 September 2023. Federal Register notice
  3. Bauman WA, et al. The effect of oxandrolone on the healing of chronic pressure ulcers in persons with spinal cord injury: a randomized trial. Ann Intern Med 2013. PMID 23689765
  4. Schroeder ET, et al. Treatment with oxandrolone and the durability of effects in older men. J Appl Physiol 2004. PMID 14578370
  5. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. WADA Prohibited List 2026
  6. Grunfeld C, et al. Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study. J Acquir Immune Defic Syndr 2006. PMID 16540931
  7. Linakis MW, et al. Stability of oxandrolone in medium-chain triglyceride oil and pharmacokinetics following buccal administration of the extemporaneous formulation in neonates and adults. J Pediatr Pharmacol Ther 2020. PMID 32265605
  8. Wolf SE, et al. Effects of oxandrolone on outcome measures in the severely burned: a multicenter prospective randomized double-blind trial. J Burn Care Res 2006. PMID 16566555
  9. Bulger EM, et al. Oxandrolone does not improve outcome of ventilator dependent surgical patients. Ann Surg 2004. PMID 15319718
  10. Gault EJ, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner's syndrome: randomised, double blind, placebo controlled trial. BMJ 2011. PMID 21493672
  11. Porro LJ, et al. Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial of safety and efficacy. J Am Coll Surg 2012. PMID 22463890
  12. Gault EJ, et al. Effect of oxandrolone and timing of pubertal induction on final height in Turner syndrome: final analysis of the UK randomised placebo-controlled trial. Arch Dis Child 2021. PMID 31862699
  13. Mavros Y, et al. Oxandrolone augmentation of resistance training in older women: a randomized trial. Med Sci Sports Exerc 2015. PMID 25899102
  14. Davis SM, et al. Effects of oxandrolone on cardiometabolic health in boys with Klinefelter syndrome: a randomized controlled trial. J Clin Endocrinol Metab 2017. PMID 27802097
  15. Lou J, et al. Oxandrolone for burn patients: a systematic review and updated meta-analysis of randomized controlled trials from 2005 to 2025. World J Emerg Surg 2025. PMID 41023744
  16. Menke LA, et al. Efficacy and safety of oxandrolone in growth hormone-treated girls with Turner syndrome. J Clin Endocrinol Metab 2010. PMID 20061421
  17. Kahn NN, et al. Effects of oxandrolone, an anabolic steroid, on hemostasis. Am J Hematol 2006. PMID 16432848
  18. Davis SM, et al. Oxandrolone treatment results in an increased risk of gonadarche in prepubertal boys with Klinefelter syndrome. J Clin Endocrinol Metab 2018. PMID 29931143
  19. US Food and Drug Administration. Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction. Federal Register 91 FR 64154, 7 October 2026. Federal Register correction